Back
IVL-BioFluidic™
Technology Introduction
BioFluidic™ is a formulation platform that enables ultra-high concentration biologics with low viscosity and high stability through microfluidic-based processes. By controlling high-molecular-weight biologics like proteins and antibodies in uniform microstructures, it minimizes aggregation and stabilizes physical properties. This offers the possibility of converting high-dose formulations that previously depended on intravenous injection to subcutaneous and self-injection. It improves dosing convenience and treatment accessibility, while expanding product competitiveness and lifecycle value through differentiated formulation strategies.
Business Model
1. Feasibility Study based Research Collaboration
BioFluidic™ conducts collaborative research based on Feasibility Studies to verify the feasibility of ultra-high concentration formulations for partners' biologic candidates. After confirming the possibility of subcutaneous conversion and technical superiority through short-term physical property and stability evaluation, we minimize development risks and expand business opportunities through a phased collaboration structure expanding to co-development or license-out.
